TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Orexo AB ( (SE:ORX) ) just unveiled an announcement.
Orexo AB has announced the appointment of its Nomination Committee for the Annual General Meeting scheduled for May 7, 2026. The committee, representing approximately 34% of the company’s voting power, includes members from Novo Holdings, The Danish Labour Market Supplementary Pension, and private investors. This strategic move ensures diverse representation and stakeholder engagement in Orexo’s governance, potentially impacting its future strategic decisions.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
More about Orexo AB
Orexo is a Swedish pharmaceutical company with 30 years of experience in developing improved pharmaceuticals using proprietary formulation technologies. The company focuses on providing innovative treatment solutions for opioid use disorder in the US market and collaborates with leading partners to develop products for other therapeutic areas globally. In 2024, Orexo reported net sales of SEK 590 million and employed 110 people. It is listed on Nasdaq Stockholm and available as ADRs on the OTCQX market in the US.
Average Trading Volume: 60,955
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.3B
For an in-depth examination of ORX stock, go to TipRanks’ Overview page.